Healthy Skepticism Library item: 6747

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Vitry A, Mansfield P.
Re: breaches of the APMA Code of Conduct
1997 Jun;

Abstract:

MaLAM has sent formal complaints to the Australian Pharmaceutical Manufacturers Association about three issues: the use of loose leaf inserts in medical journals; the marketing of Lamictal (lamotrigine) by Glaxo-Wellcome which omitted key safety information; the indirect promotion of Aurorix (moclobemide) in the mass media.

Keywords:
*analysis/Australia/developed countries/Glaxo-Wellcome/Hoffman LaRoche/Lamictal/lamotrigine/Aurorix/moclobemide/DTCA/ direct-to-consumer advertising/ safety & risk information/ Australian Pharmaceutical Manufacturers Association/ Code of Conduct (Aus)/MaLAM/Medical Lobby for Appropriate Marketing/EVALUATION OF PROMOTION: DIRECT-TO-CONSUMER ADVERTISING/EVALUATION OF PROMOTION: DRUG SAFETY/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPED COUNTRIES/REGULATION, CODES, GUIDELINES: INDUSTRY SELF-REGULATION